BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...

Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

Adding 75mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million. HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...